The microscopy equipment industry is growing and increasingly competitive, with competition based on brand recognition, product quality, price, and innovation. The Company operates in this industry, primarily in Singapore and Indonesia, and is expanding across Southeast Asia and South Asia. The industry faces structural forces such as the entry of new competitors, market consolidation, and the presence of formidable competitors with greater scale and financial resources. The Company's products are used in fields such as manufacturing, research and development, biomedical, semiconductors, Printed Circuit Board, electronics, precision engineering, injection molding, research, healthcare, QA/QC, and diagnostics.
The Company competes with well-recognized brands including Keyence Corp. (TYO:6861), Nikon Corp. (TYO:7731), Olympus Corp. (TYO: 7733), and Hirox Co. Ltd. The Company believes it is well positioned to compete due to its strong and stable relationships with suppliers and customers, experienced management team, integrated software solutions, innovative and turn-key solutions, adaptive business model, and reliable after-sales support. For the financial years ended April 30, 2025 and 2026, the top 5 customers accounted for 85% and 81% of total revenue, respectively.
The Company generates revenue through the sale and development of microscopy equipment and related software. Revenue is derived from a combination of distributor and direct customer sales channels, primarily in Singapore and Indonesia. The business model includes both product sales and service revenue from maintenance-based contracts. The Company's customer base includes manufacturing companies, biomedical service providers, and research and development institutions. The Company is implementing a direct sales strategy to diversify its customer base and reduce reliance on distributors.
The Company's product range includes the Optonano series, which offers super-resolution imaging down to 137nm; the PT-Industrial (PT-I) series for material study, failure analysis, and quality control; the PT-Metrology (PT-M) series for quick dimensional measurements; the PT-Biology (PT-B) series for the biomedical sector; the PT-Stereo (PT-S) series for quality assurance and control; and the PT-Zoom (PT-Z) series providing three-dimensional magnified views. For the year ended April 30, 2025 and April 30, 2026, the provision of microscopy products and components contributed to 95.9% and 91.8% of revenue, respectively. The Company also provides proprietary software with AI components for image-based defect detection and quality control.
The Company released its second series of products for bio-medical applications in September 2024, targeting digital pathology. The Company is working with a Korean microscopy company to develop products using Optical Coherence Tomography technology, with development expected to be completed by December 31, 2026. In June 2025, the Company reduced its workforce from 25 to 10 full-time employees. On March 30, 2026, the Company adopted the 2026 Equity Incentive Plan with a maximum of 2,741,350 Class A ordinary shares available for issuance. On May 18, 2026, the Company filed a Registration Statement on Form F-1 for a proposed public offering.
Revenue for the year ended April 30, 2026 was S$132,077, compared to S$167,707 for the year ended April 30, 2025, a decline primarily due to delayed sales orders. Net loss for the year ended April 30, 2026 was S$6,157,779, compared to S$5,137,064 for the year ended April 30, 2025. Accumulated deficit as of April 30, 2026 was S$18,324,909. The Company has incurred operating losses since inception and has substantial doubt about its ability to continue as a going concern.
The Company plans to strengthen its market position in Singapore and Indonesia and progressively expand into the Southeast Asian region. Malaysia is identified as the principal near-term expansion market, where the Company is establishing direct customer relationships. The Company is also exploring joint ventures and strategic alliances in the Southeast Asia market, including a loan to PT Neura Integrasi Solusi for biomedical scanning software development, which has been fully written off as at April 30, 2026. The Company is working with a Korean microscopy company on Optical Coherence Tomography technology, with development expected to be completed by December 31, 2026.
The Company plans to broaden its marketing approach, shifting to digital marketing in Southeast Asia, China, Taiwan, and Korea, and expanding physical presence to the Middle East, the United States, and Europe. The Company intends to widen its product range through continuous improvements to current products and new product series development, including AI components for digital pathology and cancer cell analysis.
The Company has reduced its monthly operating expenses to below S$200,000 following a workforce reduction from 25 to 10 full-time employees in June 2025. Management believes these cost management measures have not adversely affected the Company's ability to support its operations or continue its direct sales strategy. The Company expects service revenue to continue to contribute a greater percentage of revenue going forward.
The Company plans to continue to provide for its capital needs through sales of its securities and/or related party advances. The Company does not expect to pay any cash dividends in the foreseeable future, intending to retain all available funds to fund development and growth.
The Company faces headwinds including customer concentration risk, with the largest customer accounting for 38% of total revenue in fiscal year 2026. The Company is susceptible to fluctuations in the prices and quantity of materials and components, with lenses sourced from Japan, Germany, and China, and light sources and electromechanical parts from the United Kingdom, Malaysia, Thailand, and Singapore. The Company also faces risks from regional and worldwide political, regulatory, social, and economic conditions, and foreign currency exchange rate fluctuations.
Management's message emphasizes the initial impact of efforts to broaden the customer base, reduce customer concentration, and improve operational efficiency. The Company believes customer diversification and cost management initiatives have begun to produce initial operational improvements. Management expects ongoing customer diversification and regional expansion efforts to increase and stabilize product sales over time. The Company's strategic priorities include strengthening market position in Singapore and Indonesia, expanding into Southeast Asia, and implementing a direct sales strategy led by the Managing Director.
Total revenue for the year ended April 30, 2026 was S$132,077 (US$103,694), compared to S$167,707 (US$131,667) for the year ended April 30, 2025. Net loss for the year ended April 30, 2026 was S$6,157,779 (US$4,834,474), compared to S$5,137,064 (US$4,033,109) for the year ended April 30, 2025. Accumulated deficit as of April 30, 2026 was S$18,324,909 (US$14,386,886), compared to S$12,167,130 (US$9,552,412) as of April 30, 2025. The loan to PT Neura Integrasi Solusi was fully written off as at April 30, 2026, with a partial impairment of S$1,223,608 (US$960,655) recorded during the year ended April 30, 2025. The Company's net losses for the years ended April 30, 2026 and April 30, 2025 were approximately S$6,157,779 and S$5,137,064, respectively. Revenue concentration from the largest customer increased from approximately 23% to approximately 38% of total revenue, while the five largest customers decreased from approximately 85% to approximately 81% of total revenue.
The Company is an early revenue stage company with substantial doubt about its ability to continue as a going concern, having incurred net losses of approximately S$6,157,779 for the year ended April 30, 2026. Customer concentration is a material risk, with the top 5 customers accounting for 81% of total revenue and the largest customer accounting for 38% in fiscal year 2026. The Company faces supply chain risks, sourcing key components from multiple countries, and is susceptible to price fluctuations and shortages. The loan to PT Neura Integrasi Solusi, amounting to S$1,623,608 as of April 30, 2025, has been fully written off as at April 30, 2026, exposing the Company to potential losses. The Company's market price has been highly volatile, with declines from US$6.46 to US$1.06 on February 13, 2026, and from US$2.65 to US$0.522 on May 29, 2026.
Analysis on 8/31/2026